Feeds

Two drug trial victims released

But one still critical

Bridging the IT gap between rising business demands and ageing tools

Doctors caring for the six human guinea pig victims of the disastrous TeGenero drug trial have discharged two of the men. Three others remain as in-patients at Northwick Park Hospital, London, while one man is still in a critical condition after being administered an experimental immune treatment more than two weeks ago.

The hospital is staying tight-lipped on the prognosis for the critical patient, but says he has shown some signs of improvement. The released volunteers will continue to receive treatment and be monitored as out-patients.

The men were given TGN1412, an antibody designed to suppress the destructive power of immune cells in diseases like rheumatoid arthritis and leukaemia. The problems didn't show up in animal trials.

Speculations about what caused the reaction have centred on contamination of the doses by bacterial toxins, and a paradoxical super-activation of the volunteer's immune system.®

Mobile application security vulnerability report

More from The Register

next story
Bad back? Show some spine and stop popping paracetamol
Study finds common pain-killer doesn't reduce pain or shorten recovery
Malaysian Airlines flight MH17 claimed lives of HIV/AIDS cure scientists
Researchers, advocates, health workers among those on shot-down plane
World Solar Challenge contender claims new speed record
One charge sees Sunswift travel 500kms at over 100 km/h
Mwa-ha-ha-ha! Eccentric billionaire Musk gets his PRIVATE SPACEPORT
In the Lone Star State, perhaps appropriately enough
SMELL YOU LATER, LOSERS – Dumbo tells rats, dogs... humans
Junk in the trunk? That's what people have
All those new '5G standards'? Here's the science they rely on
Radio professor tells us how wireless will get faster in the real world
The Sun took a day off last week and made NO sunspots
Someone needs to get that lazy star cooking again before things get cold around here
prev story

Whitepapers

Designing a Defense for Mobile Applications
Learn about the various considerations for defending mobile applications - from the application architecture itself to the myriad testing technologies.
How modern custom applications can spur business growth
Learn how to create, deploy and manage custom applications without consuming or expanding the need for scarce, expensive IT resources.
Reducing security risks from open source software
Follow a few strategies and your organization can gain the full benefits of open source and the cloud without compromising the security of your applications.
Boost IT visibility and business value
How building a great service catalog relieves pressure points and demonstrates the value of IT service management.
Consolidation: the foundation for IT and business transformation
In this whitepaper learn how effective consolidation of IT and business resources can enable multiple, meaningful business benefits.